Skip to main content
Premium Trial:

Request an Annual Quote

Epigenomics' Q1 Revenues Rise, Net Loss Declines

NEW YORK (GenomeWeb News) – Epigenomics today reported that its first-quarter revenues increased 36 percent due primarily to milestone payments received from Abbott and new collaborations, and its net loss dropped 16 percent year over year.

The German molecular diagnostics firm reported total revenues of €1.24 million (US$1.7 million), up 36 percent from €920,000 for the first quarter of 2008. Its diagnostics business accounted for 70 percent of its total revenue, while its biomarker service revenue accounted for 30 percent.

It attributed part of the increase its ongoing collaboration with Abbott. The firms are collaborating on an mSEPT9 test kit for colorectal cancer that will run on Abbott's m2000 instrument. Epigenomics said that the test is in the final stages of development and clinical validation, and it expects Abbott to launch the test in Europe in the fourth quarter of this year.

Epigenomics' net loss for the quarter declined 16 percent to €2.4 million from €2.9 million.

The company's R&D costs decreased 25 percent to €1.8 million from €2.4 million, and its marketing and business development costs decreased 6 percent to €210,000 from €230,000 year over year.

Epigenomics finished the quarter with €23.1 million.

In February, Epigenomics raised €5.18 million ($6.6 million) through the placement of 2,671,088 new shares at an issue price of €1.94 per share. A subsidiary of BB Medtech and funds managed by Abingworth subscribed for all the new shares.

The firm expects to generate revenue of at least €3 million for fiscal year 2009, with a cash burn rate of below €10 million.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.